Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01347762 · ClinicalTrials.gov registry record · Phase 2
Nabilone for Cannabis Dependence: A Pilot Study
A Phase 2 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT01347762 is a Phase 2 study that has completed, run by Mclean Hospital. The registered enrollment target is 84 participants.
The verdict
NCT01347762, a Phase 2 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
Cannabis use disorders are an important public health problem in the United States, but there are no effective medications available to treat these disorders. The investigators intend to test a medication with interesting properties, nabilone, as a treatment for cannabis dependence and to study the relationship of this treatment with the brain using functional MRI brain scans. Nabilone and marijuana have similar effects upon behaviors and the human body, suggesting that nabilone may decrease cannabis withdrawal symptoms while allowing treatment-seeking patients to benefit from behavioral treatments when they are trying to stop using cannabis. The investigators propose to assess the relationship of nabilone, when added to behavioral treatment, on cannabis use patterns in cannabis-dependent patients. The investigators also aim to determine the effects of nabilone on performance on neuropsychological tests and to assess the correlation of neuropsychological performance to brain changes using functional MRI brain scans. The investigators hypothesize that patients receiving nabilone will reduce their use of cannabis more than patients receiving placebo during this 10-week treatment trial.
Interventions
- DRUG Placebo
- DRUG Nabilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2010-06 |
| Est. Completion | 2017-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01347762
The ClinicalTrials.gov registry entry for NCT01347762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01347762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01347762 about?
NCT01347762 is a clinical study titled "Nabilone for Cannabis Dependence: A Pilot Study". Cannabis use disorders are an important public health problem in the United States, but there are no effective medications available to treat these disorders. The investigators intend to test a medication with interesting properties, nabilone, as a treatment for cannabis dependence and to study the ...
What is the current status of trial NCT01347762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2010-06. Estimated completion is 2017-06-09.
What interventions are being tested in trial NCT01347762?
The interventions under investigation include: Placebo (DRUG), Nabilone (DRUG).
Who is sponsoring clinical trial NCT01347762?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.